Thymalin: Activation of Differentiation of Human Hematopoietic Stem Cells
Khavinson VK, Linkova NS, Kvetnoy IM, Polyakova VO, Drobintseva AO, Kvetnaia TV, Ivko OM · 2020 · Bull Exp Biol Med. 2020;170(1):118-122. PMID 33237528
This source appears in the Thymalin–Dalargin evidence review. A single-agent experiment, comparative study or patent alternative is not automatically a combined-treatment trial.
Reported findings and study design
Reported findings
CD28 expression increased 6.8-fold, while CD44 and CD117 expression fell by a reported factor of 2–3. These are differentiation-associated markers, not a 6.8-fold increase in functional T-cell production.
Human hematopoietic-cell differentiation experiment; donor count, culture size and uncertainty not provided in the checked abstract.
Protocol information
Dose, route and treatment schedule are not sufficiently described in the checked abstract.
Protocol source ↗ · Original indexed abstract; protocol unavailable
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| CD28 expression | 6.8-fold increase reported | Cell differentiation marker; raw levels, denominator and effect uncertainty unavailable |
| CD44 and CD117 expression | Reported 2–3-fold reductions | Marker changes alone do not establish lineage conversion or improved patient immunity |
| Clinical and protocol gap | Dose, duration and donor counts unavailable in the checked abstract; no patient outcome measured |
Findings apply to this preparation, assay and comparison. They do not establish Thymalin–Dalargin combination efficacy or a safe combined regimen.
Source for the extracted data ↗ · Checked 2026-11-08
Molekul summary of the linked publication. Educational information, not medical advice. Seek qualified healthcare help for medical conditions.
Methods, limitations & source review
Study limitations
- Publisher preview and indexed abstract checked; full experimental methods were not recovered.
- No dose, raw marker values, sample count or error bars supplied by the checked abstract.
- Markers indirectly support a differentiation hypothesis; they do not establish antiviral prevention or Thymalin–Dalargin efficacy.
Publication counts are not counts of independent trials. Reviews, translations and reports sharing participants may overlap. Findings apply to the studied preparation, population and endpoints.
Document format: Original indexed abstract
Review depth: Indexed abstract and citation checked; full original outcome tables not recovered
Source access and review scope
Original PubMed / Europe PMC indexed abstract checked. Missing group sizes, doses, raw outcomes and uncertainty are not reconstructed.
Recorded source-check date: 2026-11-08. This date does not imply a completed systematic review.
Source type: Original journal publication
Citation and original source
Original source: Khavinson VK, Linkova NS, Kvetnoy IM, Polyakova VO, Drobintseva AO, Kvetnaia TV, Ivko OM. Thymalin: Activation of Differentiation of Human Hematopoietic Stem Cells Bull Exp Biol Med. 2020;170(1):118-122. PMID 33237528 2020.
Molekul research summary: https://molekul.io/research/thymalin-differentiation-2020. Cite the original publication for its findings and this page when referring to Molekul’s summary or evidence appraisal.
Bibliography entry